October 6, 2026 · Journal of hepatology · DOI: 10.1016/j.jhep.2026.10.002

First-line durvalumab and tremelimumab in poor-prognosis unresectable hepatocellular carcinoma: Phase IIIb single-arm SIERRA study.

Listen to this summary

The SIERRA phase IIIb study asked whether the first-line dual immunotherapy regimen STRIDE (single tremelimumab plus regular durvalumab) can be given safely and effectively to patients with unresectable hepatocellular carcinoma who are typically excluded from phase III trials, namely those with Child-Pugh B7/B8 liver function, ECOG performance status 2, or main portal vein thrombosis (Vp4). In 111 participants, the rate of Grade 3/4 treatment-related adverse events within 6 months was 19.8%, and the objective response rate was 14.4% (6.8% in Child-Pugh B7/B8, 21.3% in ECOG PS 2, and 15.0% in Vp4). The authors conclude that STRIDE offers a favourable risk-benefit profile in this underrepresented, high-need population.

Stephen L Chan, Masatoshi Kudo, Bruno Sangro, Robin Kate Kelley, Jee Hyun Kim, Binh Pham, Jung Yong Hong, Dirk-Thomas Waldschmidt, Donatella Marino, René Gerolami, Adam M Burgoyne, Gianluca Masi, Robert John Walsh, Jens U Marquardt, Ugochinyere Emeribe, Kavitha Balaji, Peng Sun, Boris Baur, Lorenza Rimassa

This is one of 33,000+ journals available on OSLR. Try it free for 14 days.

Free 14-day trial. 33,000+ journals. Cancel anytime.

14-day free trial. No commitment.

“

"Oslr has become part of my weekly routine on my day off. The clinical relevance of the summaries is outstanding — I'd rate it 9/10. Being able to consume research hands-free is a huge advantage for busy physicians."

Dr. Jennifer Thompson

Dr. Jennifer Thompson

Portland, OR

Stay current without falling behind

33,000+ journals. 3-minute audio summaries. Free for 14 days.

Download on the App StoreGet it on Google Play